The cortical serotonin2A receptor and the pathology of schizophrenia: A likely accomplice

Journal of Neurochemistry

Volumn 85, Issue 1, 2003, Pages 1-13

  Dean, Brian ^a  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

Author keywords

Antipsychotic drugs; Frontal cortex; Post mortem; Serotonin

Indexed keywords

CINANSERIN; CLOZAPINE; HALOPERIDOL; KETANSERIN; LYSERGIC ACID; LYSERGIDE; MESSENGER RNA; METHYSERGIDE; NEUROLEPTIC AGENT; PIPAMPERONE; RADIOLIGAND; SEROTONIN 2A RECEPTOR; SPIPERONE; SEROTONIN RECEPTOR;

ALLELE; AUTOPSY; CENTRAL NERVOUS SYSTEM; COMPLEX FORMATION; DISEASE TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; FRONTAL CORTEX; GENE ACTIVITY; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MITOGENESIS; MOLECULAR CLONING; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; PSYCHOPHARMACOLOGY; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC TRANSMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; SPROUTING; ANIMAL; BRAIN CORTEX; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GENETICS; METABOLISM; PATHOLOGY; RAT;

ANIMALS; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0037374767     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.01693.x     Document Type: Review

References (95)

1. Andree T. H., Mikuni M., Tong C. Y., Koenig J. I. and Meltzer H. Y. (1986) Differential effect of subchronic treatment with various neuroleptic agents on serotonin2 receptors in rat cerebral cortex. J. Neurochem. 46, 191-197.
2. Arora R. C. and Meltzer H. Y. (1991) Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J. Neural Transm. Gen. Sect. 85, 19-29.
3. Arranz M., Collier D., Sodhi M., Ball D., Roberts G., Price J., Sham P. and Kerwin R. (1995) Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 346, 281-282.
4. Arranz M. J., Collier D. A., Munro J., Sham P., Kirov G., Sodhi M., Roberts G., Price J. and Kerwin R. W. (1996a) Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci. Lett. 217, 177-178.
5. Arranz, M. J., Lin M. W., Powell J., Kerwin R. and Collier D. (1996b) 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 347, 1831-1832.
6. Arranz, M. J., Munro J., Owen M. J., Spurlock, G., Sham P. C., Zhao J., Kirov G., Collier D. A. and Kerwin R. W. (1998) Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol. Psychiatry 3, 61-66.
7. Ashcroft D. M., Frischer M., Lockett J. and Chapman S. R. (2002) Variations in prescribing atypical antipsychotic drugs in primary care: cross-sectional study. Pharmacoepidemiol. Drug Saf 11, 285.
8. Azmitia E. C. (2001) Modern views on an ancient chemical: serotonin effects on cell proliferation, maturation, and apoptosis. Brain Res. Bull. 56, 413-424.
9. Baldessarini R. J. and Frankenburg F. R. (1991) Clozapine. A novel antipsychotic agent. N. Engl. J. Med. 324, 746-754.
10. Basile V. S., Ozdemir V., Masellis M., Meltzer H. Y., Lieberman J. A., Potkin S. G., Macciardi F. M., Petronis A. and Kennedy J. L. (2001) Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol. Psychiatry 6, 230-234.
11. Bennett J. P. Jr, Enna S. J., Bylund D. B., Gillin J. C., Wyatt R. J. and Snyder S. H. (1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psych. 36, 927-934.
12. Borison R. L., Pathiraja A. P., Diamond B. I. and Meibach R. C. (1992) Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol. Bull. 28, 213-218.
13. Breier A. (1995) Serotonin, schizophrenia and antipsychotic drug action. Schizophr Res. 14, 187-202.
14. Buckland P. R., D'Souza U., Maher N. A. and McGuffin P. (1997) The effects of antipsychotic drigs on the mRNA levels of serotonin 5HT2A and 5HT2c receptors. Mol. Brainres. 48, 45-52.
15. Bunzel R., Blumcke I., Cichon S., Normann S., Schramm J., Propping P. and Nothen M. M. (1998) Polymorphic imprinting of the serotonin-2A (5-HT2A) receptor gene in human adult brain. Brain Res. Mol Brain Res. 59, 90-92.
16. Burnet P. W., Chen C. P., McGowan S., Franklin M. and Harrison P. J. (1996a) The effects of clozapine and haloperidol on serotonin-1A-2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain. Neuroscience 73, 531-540.
17. Burnet P. W., Eastwood S. L. and Harrison P. J. (1996b) 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15, 442-455.
18. Cameron A. M., Oram J., Geffen G. M., Kavanagh D. J., McGrath J. J. and Geffen L. B. (2002) Working memory correlates of three syndrom clusters in schizophrenia. Psychiatr. Res. 110, 49-61.
19. Chen C. H., Lee Y. R., Wei F. C., Koong F. J., Hwu H. G. and Hsiao K. J. (1997) Lack of allelic association between 102T/C polymorphism of serotonin receptor type 2A gene and schizophrenia in Chinese. Psychiatr. Genet. 7, 35-38.
20. Chen R. Y., Sham P., Chen E. Y., Li T., Cheung E. F., Hui T. C., Kwok C. L., Lieh-Mak F., Zhao J. H., Collier D. and Murray R. (2001) No association between T102C polymorphism of serotonin-2A receptor gene and clinical phenotypes of Chinese schizophrenic patients. Psychiatry Res. 105, 175-185.
21. Clifford C. P. and Nunez D. J. (1996) 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 347, 1830.
22. Cornea-Hebert V., Riad M., Wu C., Singh S. K. and Descarries L. (1999) Cellular and subcellular distribution of the serotonin 5-HT2A receptor in the central nervous system of adult rat. J. Comp Neurol. 409, 187-209.
23. Crow T. J. (1996) 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 347, 1832.
24. Dean B. and Hayes W. (1996) Decreased frontal cortical serotonin2A receptors in schizophrenia, Schizophr. Res. 21, 133-139.
25. Dean B., Hayes W., Opeskin K., Naylor L., Pavey G., Hill C., Keks N. and Copolov D. L. (1996) Serotonin2 receptors and the serotonin transporter in the schizophrenic brain. Behav. Brain Res. 73, 169-175.
26. Dean B., Hayes W., Hill C. and Copolov D. (1998) Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon? Mol. Chem. Neuropathol. 34, 133-145.
27. Dean B., Hussain T., Hayes W., Scarr E., Kitsoulis S., Hill C., Opeskin K. and Copolov D. L. (1999a) Changes in serotonin2A and GABA (A) receptors in schizophrenia: studies on the human dorsolateral prefrontal cortex. J. Neurochem. 72, 1593-1599.
28. Dean B., Tomaskovic-Crook E., Opeskin K., Keks N. and Copolov D. (1999b) No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem. Int. 34, 109-115.
29. Dean B., Pavey G., McLeod M., Opeskin K., Keks N. and Copolov D. (2001) A change in the density of [(3) H]flumazenil, but not [(3) H]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder. J. Affect. Disord. 66, 147-158.
30. Doherty M. D. and Pickel V. M. (2000) Ultrastructural localization of the serotonin 2A receptor in dopaminergic neurons in the ventral tegmental area. Brain Res. 864, 176-185.
31. Duinkerke S. J., Botter P. A., Jansen A. A., van Dongen P. A., van Haaften A. J., Boom A. J., van Laarhoven J. H. and Busard H. L. (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. Br. J. Psychiatry 163, 451-455.
32. Eastwood S. L., Burnet P. W., Gittins R., Baker K. and Harrison P. J. (2001) Expression of serotonin 5-HT (2A) receptors in the human cerebellum and alterations in schizophrenia. Synapse 42, 104-114.
33. Erdmann J., Shimron-Abarbanell D., Rietschel M., Albus M., Maier W., Korner J., Bondy B., Chen K., Shih J. C., Knapp M., Propping P. and Nothen M. M. (1996) Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum. Genet. 97, 614-619.
34. Gaddum J. H. and Hameed K. A. (1954) Drugs which antagonize 5-hydroxytryptamine. Br. J. Pharmacol. 9, 240-248.
35. Gray J. A. and Roth B. L. (2001) Paradoxical trafficking and regulation of 5-HT (2A) receptors by agonists and antagonists. Brain Res. Bull. 56, 441-451.
36. Gurevich E. V. and Joyce J. N. (1997) Alterations in the cortical serotonergic system in schizophrenia: a postmortem study. Biol. Psychiatry 42, 529-545.
37. Hawi Z., Myakishev M. V., Straub R. E., O'Neill A., Kendler K. S., Walsh D. and Gill M. (1997) No association or linkage between the 5-HT2a/T102C polymorphism and schizophrenia in Irish families. Am. J. Med. Genet 74, 370-373.
38. Hernandez I. and Sokolov B. P. (2000) Abnormalities in 5-HT2A receptor mRNA expression in frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic treatment. J. Neurosci. Res. 59, 218-225.
39. Hoyer D., Clarke D. E., Fozard J. R., Hartig P. R., Martin G. R., Mylecharane E. J., Saxena P. R. and Humphrey P. P. (1994) International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46, 157-203.
40. Huttunen M. (1995) The evolution of the serotonin-dopamine antagonist concept. J. Clin. Psychopharmacol. 15, 4S-10S.
41. Ishigaki T., Xie D. W., Liu J. C., Nakamura Y., Zhang H. Y., Tani K., Shimazu Y., Chen K., Shih J. C., Miyasato K., Ohara K. and Ohara K. (1996) Intact 5-HT2A receptor exons and the adjoining intron regions in schizophrenia. Neuropsychopharmacology 14, 339-347.
42. Ito H., Nyberg S., Halldin C., Lundkvist C. and Farde L. (1998) PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907. J. Nucl. Med. 39, 208-214.
43. Jonsson E., Nothen M. M., Bunzel R., Propping P. and Sedvall G. (1996) 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 347, 1831.
44. Joyce J. N., Shane A., Lexow N., Winokur A., Casanova M. F. and Kleinman J. E. (1993) Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8, 315-336.
45. Kouzmenko A. P., Hayes W. L., Pereira A. M., Dean B., Bumet P. W. and Harrison P. J. (1997) 5-HT2A receptor polymorphism and steady state receptor expression in schizophrenia. Lancet 349, 1815.
46. Kouzmenko A. P., Scaffidi A., Pereira A. M., Hayes W. L., Copolov D. L. and Dean B. (1999) No correlation between A (-1438) G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. Hum. Hered. 49, 103-105.
47. Kroeze W. K. and Roth B. L. (1998) The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis. Biol. Psychiatry 44, 1128-1142.
48. Laruelle M., Abi-Dargham A., Casanova M. F., Toti R., Weinberger D. R. and Kleinman J. E. (1993) Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch. Gen. Psych. 50, 810-818.
49. Lewis R., Kapur S., Jones C., DaSilva J., Brown G. M., Wilson A. A., Houle S. and Zipursky R. B. (1999) Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neurolepticnaive patients and normal subjects. Am. J. Psychiatry 156, 72-78.
50. Leysen J. E., Niemegeers C. J., Van Nueten J. M. and Laduron P. M. (1982) [3H]Ketanserin (R. 41, 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol. Pharmacol. 21, 301-314.
51. Malhotra A. K., Goldman D., Buchanan R., Breier A. and Pickar D. (1996a) 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 347, 1830-1831.
52. Malhotra A. K., Goldman D., Ozaki N., Breier A., Buchanan R. and Pickar D. (1996b) Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine. Am. J. Psychiatry 153, 1092-1094.
53. Masellis M., Paterson A. D., Badri F., Lieberman J. A., Meltzer H. Y., Cavazzoni P. and Kennedy J. L. (1995) Genetic variation of 5-HT2A receptor and response to clozapine. Lancet 346, 1108.
54. Masellis M., Basile V., Meltzer H. Y., Lieberman J. A., Sevy S., Macciardi F. M., Cola P., Howard A., Badri F., Nothen M. M., Kalow W. and Kennedy J. L. (1998) Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 19, 123-132.
55. Meaney M. J., Diorio J., Francis D., LaRocque S., O'Donnell D., Smythe J. W., Sharma S. and Tannenbaum B. (1994) Environmental regulation of the development of glucocorticoid receptor systems in the rat forebrain. The role of serotonin. Ann. NY Acad. Sci. 746, 260-273.
56. Meltzer H. Y. (1976) Biochemical studies in schizophrenia. Schizophr Bull. 2, 10-18.
57. Meltzer H. Y. (1997) Treatment-resistant schizophrenia - the role of clozapine. Curr. Med. Res. Opin. 14, 1-20.
58. Mikuni M. and Meltzer H. Y. (1984) Reduction of serotonin-2 receptors in rat cerebral cortex after subchronic administration of imipramine, chlorpromazine, and the combination thereof. Life Sci. 34, 87-92.
59. Mita T., Hanada S., Nishino N., Kuno T, Nakai H., Yamadori T., Mizoi Y. and Tanaka C. (1986) Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol. Psychiatry 21, 1407-1414.
60. Ngan E. T., Yatham L. N., Ruth T. J. and Liddle P. F. (2000) Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18) F]setoperone. Am. J. Psychiatry 157, 1016-1018.
61. Nothen M. M., Rietschel M., Erdmann J., Oberlander H., Moller H. J., Nober D. and Propping P. (1995) Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 346, 908-909.
62. O'Dell S. J., La Hoste G. J., Widmark C. B., Shapiro R. M., Potkin S. G. and Marshall J. F. (1990) Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6, 146-153.
63. Ohara K., Ino A., Ishigaki T., Tani K., Tsukamoto T., Nakamura Y. and Ohara K. (1997) Analysis of the 5′-flanking promoter region of the 5-HT2A receptor gene in schizophrenia. Neuropsychopharmacology 17, 274-278.
64. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y. and Toru M. (2000) Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci. 66, 2455-2464.
65. Pasqualetti M., Nardi I., Ladinsky H., Marazziti D. and Cassano G. B. (1996) Comparative anatomical distribution of serotonin 1A, ID alpha and 2A receptor mRNAs in human brain postmortem. Brain Res. Mol Brain Res. 39, 223-233.
66. Pasqualetti M., Ori M., Castagna M., Marazziti D., Cassano G. B. and Nardi I. (1999) Distribution and cellular localization of the serotonin type 2C receptor messenger RNA in human brain. Neuroscience 92, 601-611.
67. de Paulis T. (2001) M-100907 (Aventis). Curr. Opin. Invest Drugs 2, 123-132.
68. Polesskaya O. O. and Sokolov B. P. (2002) Differential expression of the 'C' and 'T' alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J. Neurosci. Res. 67, 812-822.
69. Pralong D., Tomaskovic-Crook E., Opeskin K., Copolov D. and Dean B. (2000) Serotonin (2A) receptors are reduced in the planum temporale from subjects with schizophrenia. Schizophr. Res. 44, 35-45.
70. Reynolds G. P., Garrett N. J., Rupniak N., Jenner P. and Marsden C. D. (1983a) Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptors. Eur. J. Pharmacol. 89, 325-326.
71. Reynolds G. P., Rossor M. N. and Iversen L. L. (1983b) Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J. Neural Transmsupplement 18, 273-277.
72. Saltzman A. G., Morse B., Whitman M. M., Ivanshchenko Y., Jaye M. and Felder S. (1991) Cloning of the human serotonin 5-HT2 and 5-HT1C receptor subtypes. Biochem. Biophys. Res. Commun 181, 1469-1478.
73. Sasaki T., Hattori M., Fukuda R., Kunugi H. and Nanko S. (1996) 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 347, 1832.
74. Scarr E., Copolov D. L. and Dean B. (2001) A proposed pathological model in the hippocampus of subjects with schizophrenia. Clin. Exp Pharmacol. Physiol. 28, 70-73.
75. Segman R. H., Heresco-Levy U., Finkel B., Goltser T., Shalem R., Schlafman M., Dorevitch A., Yakir A., Greenberg D., Lemer A. and Lerer B. (2001) Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry 6, 225-229.
76. Shinkai T., Ohmori O., Kojima H., Terao T., Suzuki T. and Abe K. (1998) Negative association between T102C polymorphism of the 5-HT2a receptor gene and schizophrenia in Japan. Hum. Hered. 48, 212-215.
77. Spurlock G., Heils A., Holmans P., Williams J., D'Souza U. M., Cardno A., Murphy K. C., Jones L., Buckland P. R., McGuffin P., Lesch K. P. and Owen M. J. (1998) A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol. Psychiatry 3, 42-49.
78. Stam N. J., Van Huizen F., Van Alebeek C., Brands J., Dijkema R., Tonnaer J. A. and Olijve W. (1992) Genomic organization, coding sequence and functional expression of human 5-HT2 and 5-HT1A receptor genes. Eur. J. Pharmacol. 227, 153-162.
79. Tan E. C., Chong S. A., Mahendran R., Dong F. and Tan C. H. (2001) Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol. Psychiatry 50, 144-147.
80. Tay A. H., Lim L. C., Lee W. L., Wong K. E., Wong L. Y. and Tsoi W. F. (1997) Association between allele 1 of T102C polymorphism, 5-hydroxytryptamine 2a receptor gene and schizophrenia in Chinese males in Singapore. Hum. Hered. 47, 298-300.
81. Trichard C., Paillere-Martinot M. L., Attar-Levy D., Blin J., Feline A. and Martinot J. L. (1998) No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr. Res. 31, 13-17.
82. Vardy M. M. and Kay S. R. (1983) LSD psychosis or LSD-induced schizophrenia? A multimethod inquiry. Arch. Gen. Psych. 40, 877-883.
83. Verhoeff N. P., Meyer J. H., Kecojevic A., Hussey D., Lewis R., Tauscher J., Zipursky R. B. and Kapur S. (2000) A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT (2A) receptor changes in schizophrenia. Psychiatry Res. 99, 123-135.
84. Virgos C., Martorell L., Valero J., Figuera L., Civeira F., Joven J., Labad A. and Vilella E. (2001) Association study of schizophrenia with polymorphisms at six candidate genes. Schizophr. Res. 49, 65-71.
85. Weinberger D. R. and Berman K. F. (1996) Prefrontal function in schizophrenia: confounds and controversies. Philos. Trans. R. Soc. Lond. B Biol. Sci. 351, 1495-1503.
86. Whitaker P. M., Crow T. J. and Ferrier I. N. (1981) Tritiated LSD binding in frontal cortex in schizophrenia. Arch. General Psychiatry 38, 278-280.
87. Wiesel F. A., Nordstrom A. L., Farde L. and Eriksson B. (1994) An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology (Berl) 114, 31-38.
88. Williams G. V., Rao S. G. and Goldman-Rakic P. S. (2002) The physiological role of 5-HT2A receptors in working memory. J. Neurosci. 22, 2843-2854.
89. Williams J., Spurlock G., McGuffin P., Mallet J., Nothen M. M., Gill M., Aschauer H., Nylander P. O., Macciardi F. and Owen M. J. (1996) Association between schizophrenia and T102C polymorphism of the 5-hydroxytryptamine type 2a-receptor gene. European Multicentre Association Study of Schizophrenia (EMASS) Group. Lancet 347, 1294-1296.
90. Williams J., McGuffin P., Nothen M. and Owen M. J. (1997) Metaanalysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. Lancet 349, 1221.
91. Wilmot C. A. and Szczepanik A. M. (1989) Effects of acute and chronic treatments with clozapine and haloperidol on serotonin (5-HT2) and dopamine (D2) receptors in the rat brain. Brain Res. 487, 288-298.
92. Woods B. T. (1998) Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am. J. Psychiatry 155, 1661-1670.
93. Wooley D. M. and Shaw E. (1953) A biochemical and pharmacological suggestion about certain mental disorders. Proc. Natl Acad. Sci. USA 40, 228-231.
94. Yoshihara K., Nakamura K., Itoh M., Ameno K., Takeuchi Y., Ijiri I. and Iwahashi K. (2000) The human serotonin receptor gene (HTR2) Msppolymorphism in Japanese schizophrenic and alcoholic patients. Neuropsychobiology 41, 124-126.
95. Yu Y. W., Tsai S. J., Yang K. H., Lin C. H., Chen M. C. and Hong C. J. (2001) Evidence for an association between polymorphism in the serotonin-2A receptor variant (102T/C) and increment of N100 amplitude in schizophrenics treated with clozapine. Neuropsychobiology 43, 79-82.